Clinical Trial Update: Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation [Phase 2]

View source ↗

Summary

A Phase 2 study of capmatinib in Chinese adults with advanced MET exon 14 skipping mutation–positive non-small cell lung cancer has completed and posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)
• Tabrecta (Capmatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2026-03-27